SHS invests in Simulands AG
The German life science and medtech investor SHS Gesellschaft für Beteiligungsmanagement mbH has made a EUR 10 million investment in Simulands AG, a Zurich-based manufacturer of simulation devices for medical training of cardiovascular interventions.
Oberland Capital closes financing agreement with Helsinn Group
VISCHER advised Oberland Capital Management LLC on its financing agreement with the Helsinn Group.
E3 Holding AG acquires the clean-tek group
E3 Holding AG, Germany, has acquired the clean-tek group from Felix Ritter.
Clean-tek is one of the pioneers in cleanroom technology - technology for sensitive areas such as pharmaceutical production, medical technology,...
AMR Action Fund invests in BioVersys AG
The AMR Action Fund, the world's largest public-private partnership investing in biotech companies that are developing antimicrobials, has invested in BioVersys AG, a clinical-stage company based in Basel, Switzerland.
Invision launches CHF 145m continuation fund
Invision has launched and successfully closed Invision Logistics LP, a CHF 145m continuation fund for the further development of Schneider Group.
Resistell AG closes series B first tranche of CHF 8.5m
Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another major step to achieving its vision by closing a first tranche of its series B financing round raising CHF 8.5m from new and existing investors.
AFINUM has sold its stake in Cotta Collection AG Upholstered Furniture-Group to L-GAM and to Gschwend AG
AFINUM has sold its stake in Cotta Collection AG Upholstered Furniture-Group to L-GAM and to Gschwend AG.
Cotta is a manufacturer of upholstered furniture in the low to medium price segment with two plants in Poland and one plant in Romania.
Hangzhou GreatStar Industrial lists GDRs on SIX Swiss Exchange
On 15 November 2022, Hangzhou GreatStar Industrial Co., Ltd., whose A Shares are listed on the Shenzhen Stock Exchange, became the eighth Chinese company that has listed global depositary receipts (GDRs) on the SIX Swiss Exchange.
Anokion raises USD 35m Financing
Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, recently closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative.
Oculis SA and European Biotech Acquisition Corp announce business combination
Oculis, SA, a global biopharmaceutical company developing treatments to save sight and improve eye care with breakthrough innovations and European Biotech Acquisition Corp (NASDAQ: EBAC), a special purpose acquisition company (SPAC), announced they have entered into a definitive business combination agreement.